A Prospective, Single-arm Phase II Clinical Study to Evaluate the Efficacy and Safety of JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer With Previous Chemotherapy Combined With PD-L1 Failure
Latest Information Update: 29 Dec 2023
At a glance
- Drugs JS 201 (Primary) ; Lenvatinib (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 25 Dec 2023 Planned End Date changed from 1 Jun 2023 to 1 Jun 2025.
- 25 Dec 2023 Planned primary completion date changed from 1 Jun 2022 to 1 Jun 2024.
- 12 Jul 2021 New trial record